Citius Oncology (CTOR) AI Stock Analysis

• Market Cap: $94.45M
• Dividend Yield: N/A
• Average Volume (3M): 176.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): -0.06
• Shares Outstanding: 88,275,210
• 10 Day Avg. Volume: 187,958
• 30 Day Avg. Volume: 176,897
• PEG Ratio: -0.45
• Price to Book (P/B): 3.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -27.08
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 23.06
• Enterprise Value/Gross Profit: 28.83
• Enterprise Value/Ebitda: -4.18
• 1Y Price Target: $6.00
• Price Target Upside: 460.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.14
• Revenue Forecast (FY): $38.87M

• Rating: 46 Neutral
• Price Target: $1.00 ▼(-6.54% Downside)
• Action: Reiterated Date: 03/04/26
• Date: Action: Reiterated 03/04/26

The score is held down primarily by weak financial performance (pre-revenue, widening losses, and increasing cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting this modestly are positive corporate developments (encouraging Phase 1 data and added funding runway), while valuation remains constrained by continued losses and no dividend.

Positive Factors

Clinical progress: LYMPHIR Phase 1

Positive investigator‑led Phase 1 data showing tolerability, effective Treg depletion and high early response rates supports repurposing LYMPHIR as an immunomodulatory adjunct to CAR‑T. This materially strengthens the pipeline and long‑term commercial opportunity if validated in larger trials.

Capital infusion / runway

The $18M registered direct offering funds the planned LYMPHIR launch and general corporate needs, extending operational runway. This enhances near‑term execution capacity for clinical, regulatory and commercial milestones, reducing immediate financing pressure as the program advances.

Low leverage / balance sheet flexibility

Relatively low reported leverage provides financial flexibility and lowers interest burden, supporting continued R&D and commercialization activity. A conservative capital structure increases optionality for partnerships, milestone financings or strategic transactions as clinical programs mature.

Negative Factors

Pre-revenue with widening losses

CTOR remains pre‑revenue with materially widening operating losses, which erode equity and increase reliance on external capital. Persistent deficits constrain the company's ability to self‑fund pivotal trials and commercialization, raising dilution and execution risk absent clinical success.

Accelerating cash burn / negative FCF

Operating cash flow turned meaningfully negative and free cash flow expanded to ~-$11.2M in 2025, indicating accelerating cash burn. Sustained negative cash generation increases the probability of additional financings and limits strategic flexibility for R&D or commercial scale‑up.

Early-stage evidence & small trial size

The encouraging Phase 1 results derive from a small, investigator‑initiated study of 14 patients and were not powered for efficacy. Clinical and regulatory uncertainty remains high; larger controlled trials are required to validate benefit and support durable commercial expansion.

Citius Oncology Business Overview & Revenue Model

Company Description

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

How the Company Makes Money

Citius Oncology makes money primarily through the research, development, and commercialization of its cancer treatment drugs. The company's revenue streams include licensing agreements, where it partners with other pharmaceutical companies to co-develop or distribute its products, and sales of approved therapies. Additionally, Citius Oncology may receive milestone payments and royalties from partnerships and collaborations with other entities in the healthcare sector. The company's earnings are influenced by the successful clinical trials and regulatory approval of its drug candidates, as well as strategic partnerships that enhance its market reach.

Citius Oncology Financial Statement Overview

Summary

Income statement and cash flow are weak: the company is pre-revenue with materially widening losses (EBIT and net loss deteriorating through 2025) and accelerating cash burn (operating cash flow turning negative and free cash flow worsening). The main offset is a relatively low-debt balance sheet, but ongoing losses and equity erosion increase funding risk.

Income Statement

CTOR remains a pre-revenue oncology company (revenue is $0 across all annual periods provided), so operating losses drive results. Losses have widened materially, with EBIT declining from about -$4.9M (2022) to -$23.5M (2025 annual), and net income also deteriorating to about -$24.8M (2025 annual) versus -$5.4M (2022). With no revenue base yet, profitability and margin indicators are not meaningful, and the trajectory points to rising spend ahead of commercialization.

Balance Sheet

The balance sheet shows relatively low leverage, with total debt of about $3.8M in 2024–2025 annual and a low debt-to-equity ratio (~0.08–0.09), which is a positive for financial flexibility. However, equity has drifted down (from ~$46.1M in 2024 to ~$44.9M in 2025 annual), consistent with ongoing losses, and returns on equity are deeply negative (roughly -46% to -55% in 2024–2025 annual). Total assets increased to ~$100.9M in 2025 annual, but the key risk is continued equity erosion if losses persist.

Cash Flow

Cash generation is weak and worsening. Operating cash flow swung from slightly positive in 2024 annual (~$0.1M) to meaningfully negative in 2025 annual (~-$5.5M), and free cash flow is consistently negative, expanding to ~-$11.2M in 2025 annual from ~-$4.9M in 2024 annual. While free cash flow can diverge from net losses due to timing and non-cash items, the overall pattern indicates increasing cash burn, which raises the likelihood of future financing needs absent a revenue inflection.

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022
Income Statement
Total Revenue	3.94M	0.00	0.00	0.00	0.00
Gross Profit	3.15M	0.00	0.00	0.00	0.00
EBITDA	-21.74M	-23.49M	-20.57M	-12.12M	0.00
Net Income	-23.64M	-24.76M	-21.15M	-12.70M	-10.87M
Balance Sheet
Total Assets	109.97M	100.94M	84.37M	47.73M	42.69M
Cash, Cash Equivalents and Short-Term Investments	7.30M	3.92M	112.00	0.00	0.00
Total Debt	3.80M	3.80M	3.80M	0.00	0.00
Total Liabilities	51.56M	56.08M	38.23M	22.20M	6.42M
Stockholders Equity	58.41M	44.87M	46.14M	25.54M	36.27M
Cash Flow
Free Cash Flow	-12.89M	-5.49M	126.35K	-601.30K	-47.97K
Operating Cash Flow	-12.89M	-5.49M	126.35K	-601.30K	-47.97K
Investing Cash Flow	-10.19M	-5.75M	-5.00M	-1.32M	-67.32M
Financing Cash Flow	30.41M	15.17M	4.87M	1.66M	67.66M

Citius Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTOR, the sentiment is Negative. The current price of 1.07 is below the 20-day moving average (MA) of 1.13, below the 50-day MA of 1.12, and below the 200-day MA of 1.63, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 43.40 is Neutral, neither overbought nor oversold. The STOCH value of 32.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTOR.

Citius Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIIB	64 Neutral	$27.60B	19.96	7.39%	―	5.00%	-1.03%
GRFS	56 Neutral	$7.35B	13.91	6.93%	1.56%	9.45%	167.00%
OGN	52 Neutral	$1.75B	9.95	30.56%	4.80%	-1.69%	-61.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTOR	46 Neutral	$94.45M	-3.95	-47.41%	―	―	―
SRXH	40 Underperform	$36.53M	-0.22	―	―	-8.12%	―

Citius Oncology Corporate Events

Citius Oncology Announces Positive Phase 1 LYMPHIR Data

On March 4, 2026, Citius Oncology reported positive topline safety and efficacy data from an investigator-initiated Phase 1 trial of LYMPHIR administered before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma patients. The study, led by investigators at the University of Minnesota and City of Hope, aimed to enhance standard lymphodepletion by using LYMPHIR to deplete regulatory T-cells ahead of CAR-T infusion.

All 14 enrolled patients completed LYMPHIR dosing and proceeded to CAR-T treatment, with the regimen showing no dose-limiting toxicities and no Grade 3 or higher LYMPHIR-related immune adverse events or infusion reactions. Investigators reported effective Treg depletion in nearly all participants and an 86% overall response rate at one month, including 57% complete and 29% partial responses, alongside one-year progression-free and overall survival rates of 77% and 84%, respectively.

Adverse events associated with LYMPHIR, such as low-grade capillary leak syndrome, fever and transient liver enzyme elevations, were described as manageable, while higher-grade cytopenias aligned with expected lymphodepletion effects and CAR-T-related toxicities were limited to low-grade cytokine release syndrome and neurotoxicity. While the Phase 1 trial was not designed or powered to determine definitive efficacy or long-term comparative outcomes, the data bolster Citius Oncology’s strategy to position LYMPHIR as an immunomodulatory adjunct to existing cancer therapies, potentially expanding its role beyond its current CTCL indication and reinforcing the company’s footprint in the immuno-oncology market.

The most recent analyst rating on (CTOR) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.

Citius Oncology Raises $18M Through Direct Offering

On December 8, 2025, Citius Oncology entered into a securities purchase agreement with an institutional investor for a registered direct offering and a concurrent private placement, raising approximately $18 million. The proceeds will support the commercial launch of LYMPHIR and general corporate purposes. The offering closed on December 10, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent. The company also amended existing warrants to reduce exercise prices and adjusted the maturity of a promissory note with Citius Pharmaceuticals.

The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.